Could Assembly Biosciences Inc (NASDAQ:ASMB) See a Reversal After Less Sellers Came In?

September 16, 2018 - By Tamara Reed

The stock of Assembly Biosciences Inc (NASDAQ:ASMB) registered a decrease of 4.66% in short interest. ASMB’s total short interest was 475,100 shares in September as published by FINRA. Its down 4.66% from 498,300 shares, reported previously. With 135,200 shares average volume, it will take short sellers 4 days to cover their ASMB’s short positions.

The stock decreased 2.71% or $0.96 during the last trading session, reaching $34.47. About 165,155 shares traded. Assembly Biosciences, Inc. (NASDAQ:ASMB) has risen 26.62% since September 16, 2017 and is uptrending. It has outperformed by 11.00% the S&P500.

Assembly Biosciences, Inc., a clinical stage biotechnology company, develops oral therapeutics for the treatment of hepatitis B virus infection and novel class of oral synthetic live biotherapeutics to restore health to a dysbiotic microbiome in the United States. The company has market cap of $877.14 million. It is involved in developing core protein allosteric modulators that modulate the HBV core protein at various points in the viral lifecycle. It currently has negative earnings. The firm also develops microbiome program, a platform that includes the identification and selection process to strain isolation and growth under current good manufacturing practice conditions; and a patent pending delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract.

Assembly Biosciences, Inc. (NASDAQ:ASMB) Ratings Coverage

Among 4 analysts covering Assembly Biosciences (NASDAQ:ASMB), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Assembly Biosciences had 5 analyst reports since April 13, 2018 according to SRatingsIntel. The rating was maintained by FBR Capital with “Hold” on Thursday, June 21. FBR Capital maintained Assembly Biosciences, Inc. (NASDAQ:ASMB) on Tuesday, May 8 with “Neutral” rating. The company was downgraded on Friday, April 13 by Chardan Capital Markets.

Another recent and important Assembly Biosciences, Inc. (NASDAQ:ASMB) news was published by Globenewswire.com which published an article titled: “Assembly Biosciences to Present at Upcoming Investor Conferences” on August 28, 2018.

Assembly Biosciences, Inc. (NASDAQ:ASMB) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.